TECH provides you with the most cutting-edge and accurate information on infectious diseases in clinical practice, so you can keep up with the latest news on chronic patients and respiratory pathologies” 

It is certainly inevitable to think of COVID-19 when discussing viral respiratory diseases. The worldwide pandemic that unleashed the proliferation of SARS-CoV-2 from Wuhan to the most distant countries revealed the vulnerability of humans to the attack of unknown pathogens. The pathology mainly affects the respiratory system and causes everything from simple colds to fatal pneumonia. This type of disease is closely associated with chronic diseases, which are considered to be one of the main causes of death, since sufferers are at greater risk of infection and the consequences are more serious in them than in healthy people.  

However, the combined advances in infectious diseases and medicine have made it possible to establish increasingly effective and specialized clinical guidelines, based on health safety and the design of exhaustive and efficient action protocols. All this is presented in this complete program that TECH and a team versed in this area have developed with the aim of serving as a guide for medical specialists during their update. This program will allow our students to delve into the latest developments in the epidemiology of infectious diseases, especially with regard to oncology or immunocompromised patients. It also focuses on the clinical management of chronic non-communicable diseases and the most frequent infections in this type of cases, with special emphasis on the advances in multi-resistance techniques and the most effective vaccines for each case.

All this in 450 hours of the best theoretical, practical and additional material, which has been condensed in a convenient and flexible 100% online format. Our students will have access to a state-of-the-art Virtual Campus where they will find all the content from any device with an Internet connection, which will allow them to take on the course load from wherever they want and without a pre-established schedule. Thus, they will benefit from an academic experience that not only adapts to the demands of clinical practice, but also to their needs in a guaranteed way.  

Through a 100% online academic experience you are guaranteed to update your knowledge on the epidemiology of infectious diseases”   

This Postgraduate diploma in Chronic and Respiratory Diseases in Clinical Practice contains the most complete and up-to-date scientific program on the market. The most important features include: 

• Case studies presented by experts in infectious diseases in clinical practice 
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice 
• Practical exercises where self-assessment can be used to improve learning 
• Its special emphasis on innovative methodologies  
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments 
• Content that is accessible from any fixed or portable device with an Internet connection 

A program that includes the latest developments in cancer management and immunosuppression when the patient has also contracted a viral infection”   

The program’s teaching staff includes professionals from the sector who contribute their work experience to this educational program, as well as renowned specialists from leading societies and prestigious universities.  
The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide immersive education programmed to learn in real situations.  

This program is designed around Problem-Based Learning, whereby students must try to solve the different professional practice situations that arise during the academic year. To that end, they will be assisted by an innovative, interactive video system created by renowned and experienced experts.   

You will have at your disposal a wide range of material to personalize your in-depth study of the different sections of the syllabus, updating your knowledge at your convenience.

Thanks to the comprehensive nature of the program's design, you will be able to delve into the latest clinical data on the most lethal respiratory infections in the world"

The curriculum has been designed with the support of the teaching team and it employs the Relearning methodology, one this university has pioneered. This made it possible to create a program at the forefront of medicine, based not only on the latest developments in infectious diseases in clinical practice, but also on the most innovative and sophisticated academic technology. Our students will benefit from a program that adapts to the demands of the field and to their own needs, guaranteeing they will update their knowledge.  

You will find dozens of hours of high-quality additional material on the Virtual Campus for you to delve into aspects such as bacteria alidade against cancer in today's medical environment”  

Module 1. Epidemiology of Infectious Diseases 

1.1. Epidemiological, Economic and Social Conditions by Continent that Favor the Emergence of Infectious Diseases 

1.1.1. Africa 
1.1.2. America 
1.1.3. Europe and Asia 

1.2. New and Emerging Diseases by Continent 

1.2.1. Morbidity and Mortality from Infectious Diseases in Africa 
1.2.2. Morbidity and Mortality from Infectious Diseases in the Americas 
1.2.3. Morbidity and Mortality from Infectious Disease in Asia 
1.2.4. Morbidity and Mortality from Infectious Diseases in Europe 

1.3. The Taxonomy of Infectious Agents 

1.3.1. Viruses 
1.3.2. Bacteria 
1.3.3. Fungi 
1.3.4. Parasites 

1.4. Properties in Microorganisms that Cause Disease 

1.4.1. Pathogenic Mechanisms 
1.4.2. Adhesion and Multiplication Mechanisms 
1.4.3. Mechanisms that Enable Nutrient Acquisition from Hosts 
1.4.4. Mechanisms that Inhibit Phagocytic Processes 
1.4.5. Mechanisms that Circumvent Immune Responses 

1.5. Microscopy and Staining 

1.5.1. Microscopes and Types of Microscopes 
1.5.2. Composite Stains 
1.5.3. Acid-Fast Microorganism Stains 
1.5.4. Stains for Cellular Structures 

1.6. Microorganism Cultures and Growth 

1.6.1. General Culture Methods 
1.6.2. Specific Culture Methods 

1.7. Effect of Chemical and Physical Agents on Microorganisms 

1.7.1. Sterilisation and Disinfection 
1.7.2. Disinfectants and Antiseptics Used in Practice 

1.8. Molecular Biology and Its Relevance to Infectious Disease Specialists 

1.8.1. Bacterial Genetics 
1.8.2. Polymerase Chain Reaction Tests 

1.9. Indication and Interpretation of Microbiological Studies

Module 2. Cancer and Immunosuppression

2.1. The Innate and Adaptive Immune Response 

2.1.1. Cells and Cytokines in Response to Infectious Agents 
2.1.2. Characteristics of the Innate Immune Response 

2.2. Immunosuppression in Different Conditions in Patients with Sepsis 

2.2.1. The Role of Cytotoxics in Immunosuppression 
2.2.2. The Role of Cytotoxics in Immunosuppression 
2.2.3. Infection in Transplant Patients 

2.3. The Oncohematological Patient with Sepsis 

2.3.1. Medullary Aplasia 
2.3.2. Neutropenia 
2.3.3. Infections in Cancer Patients 

2.4. Sepsis in Diabetic Patients 

2.4.1. The Immune System in Diabetes Mellitus 
2.4.2. Main Infections in Diabetic Patients 

2.5. Comprehensive Approach to Immunocompromised Patients with Sepsis 

2.5.1. Diagnostic Considerations 
2.5.2. Therapeutic Measures 

2.6. The Link between Cancer and Microorganisms 

2.6.1. Oncogenesis and Infection 
2.6.2. Virus and Cancer 

2.6.2.1. Epstein-Barr Virus 
2.6.2.2. Hepatitis B and C Viruses 
2.6.2.3. Human Immunodeficiency Virus 
2.6.2.4. T-Cell Lymphoma/Leukaemia Viruses 
2.6.2.5. Kaposi's Sarcoma-Associated Herpesvirus 

2.7. Bacterias and Cancer 

2.7.1. Helicobacter Pylori 

2.8. Parasites and Cancer 

2.8.1. Schistosoma Haematobium 
2.8.2. Opisthorchis Viverrini 

2.9. Bacteria Allies against Cancer

Module 3. Chronic Non-Communicable Diseases and Infections 

3.1. Infections and Chronic Inflammatory Response 

3.1.1. Immune System Cells in Chronic Inflammatory Response to Infections 
3.1.2. The Granulomatous Response and Delayed-type Hypersensitivity 
3.1.3. The Role of Chemical Mediators in Chronic Inflammatory Response 

3.2. Stress, Immunity and Infectious Agents 

3.2.1. Neurological, Endocrine and Immune Interrelationships 
3.2.2. Stress and Immune Response 
3.2.3. Chronic Fatigue Syndrome and Infections 

3.3. Atherosclerosis, Cardiovascular Disease and the Role of Infectious Agents 

3.3.1. The Role of Infectious Agents in Atherosclerosis 
3.3.2. Cardiovascular Disease Mortality and Infectious Agents 
3.3.3. Cardiovascular Mortality in Pneumonia Patients 

3.4. Digestive Diseases Associated with Infectious Microorganisms 

3.4.1. Gut Flora and Important Functions 
3.4.2. Gastroduodenal Peptic and Helicobacter Pylori Disease 
3.4.3. Inflammatory Bowel Disease and Infections 
3.4.4. Whipple’s Disease 

3.5. Neurological Diseases and Infections 

3.5.1. Dementia and Infections 
3.5.2. Multiple Sclerosis and its Relationship to Certain Infectious Agents 
3.5.3. Guillain-Barré Syndrome, Immunity and Viral Infections 
3.5.4. Parkinson’s Disease and Infections 

3.6. Endocrinopathies and Infections 

3.6.1. Mellitus Diabetes and Infections 
3.6.2. Chronic Thyroiditis and Infections 

3.7. The Infectious Theory of Rheumatic Diseases 

3.7.1. Rheumatoid Arthritis 
3.7.2. Systemic Lupus Erythematosus 
3.7.3. Seronegative Spondyloarthropathies 
3.7.4. Wegener's Granulomatosis 
3.7.5. Polymyalgia Rheumatica

Module 4. The Most Lethal Respiratory Infections 

4.1. Immunology and Defence Mechanisms of the Respiratory System 
4.2. Influenza and Other Lethal Viral Infections 
4.2.1. Influenza Epidemics 
4.2.2. H1N1 Influenza 

4.2.3. Vaccine Against Influenza and the Prevention of Mortality 

4.3. Bacterial Pneumonia: The Captain of the Armies of Death 
4.3.1. Community-Acquired Pneumonia (CAP) 
4.3.2. Intrahospital Pneumonia 
4.3.3. Pneumonia Associated with Healthcare 

4.4. Tuberculosis 

4.4.1. Epidemiology 
4.4.2. Pathobiology 
4.4.3. Classification 
4.4.4. Clinical Picture 
4.4.5. Diagnosis 
4.4.6. Treatment 

4.5. Loeffler's Syndrome and Eosinophilic Syndromes 

4.5.1. Pulmonary Phase of Parasites 
4.5.2. Clinical and Radiological Manifestations 
4.5.3. Other Eosinophilic Pneumonias 

4.6. Antimicrobials and the Respiratory System 

4.6.1. Antimicrobials Effective in the Respiratory System 
4.6.2. The Immunomodulatory Role of Macrolides in Pneumonia 

Module 5. Multi-Resistance and Vaccines 

5.1. The Silent Epidemic of Antibiotic Resistance 

5.1.1. Globalization and Resistance 
5.1.2. Change from Susceptible to Resistant of the Microorganisms 

5.2. The Main Genetic Mechanisms of Antimicrobial Resistance 

5.2.1. Describe the Main Mechanisms of Antimicrobial Resistance 
5.2.2. Selective Antimicrobial Pressure on Antimicrobial Resistance 

5.3. Superbugs 

5.3.1. Pneumococcus Resistant to Penicillin and Macrolides 
5.3.2. Multidrug-Resistant Staphylococci 
5.3.3. Resistant Infections in Intensive Care Units (ICUs) 
5.3.4. Resistant Urinary Tract Infections 
5.3.5. Other Multi-Resistant Microorganisms 

5.4. Resistant Viruses 

5.4.1. HIV 
5.4.2. Influenza 
5.4.3. Hepatitis Viruses 

5.5. Multidrug-Resistant Malaria 

5.5.1. Chloroquine Resistance 
5.5.2. Resistance to Other Antimalarials 

5.6. The Main Genetic Studies of Antimicrobial Resistance 

5.6.1. Interpretation of Resistance Studies 

5.7. Global Strategies for Reducing Antimicrobial Resistance 

5.7.1. The Control of Prescribing Antibiotics 
5.7.2. Microbiological Mapping and Clinical Practice Guidelines 

5.8. Overview of Vaccines 

5.8.1. Immunological Basis of Vaccination 
5.8.2. The Process of Vaccination Production 
5.8.3. Quality Control of Vaccines 
5.8.4. Vaccine Safety and Major Adverse Events 
5.8.5. Clinical and Epidemiological Studies for Vaccine Approval 

5.9. The Use of Vaccines 

5.9.1. Vaccine-Preventable Diseases and Vaccination Programmes 
5.9.2. Global Experiences of the Effectiveness of Vaccination Programmes 
5.9.3. Vaccine Candidates for New Diseases 

Cardiovascular, neurological, endocrinopathic diseases? With this program, you will be able to implement the best and most innovative strategies in your practice to fight against infections”